泊洛沙姆407原位凝胶在鼻腔给药系统中的应用  

Poloxamer 407 in situ gel for nasal delivery system

作　　者：章俊云 罗华菲[1] 王浩[1] 

机构地区：[1]中国医药工业研究总院药物制剂国家工程研究中心,上海201203

出　　处：《世界临床药物》2016年第6期417-422,共6页World Clinical Drug

基　　金：国家"重大新药创制"科技重大专项(编号:2014ZX09507006-002)

摘　　要：鼻腔给药可因黏膜纤毛的清除作用而影响生物利用度,使用吸收促进剂虽然可以达到一定的效果,但会损害鼻黏膜。原位凝胶经鼻腔给药,既避免了药物的胃肠首过效应,又因其能延长药物在给药部位滞留时间而提高疗效。本文在对近年来国内外文献调研的基础上综述了泊洛沙姆407原位凝胶用于鼻腔给药系统的研究状况,包括泊洛沙姆407原位凝胶的概念及特点、影响药物吸收的制剂因素和应用等。Nasal administration may result in poor bioavailability due to the removal of mucosal cilia. Generally, the absorption enhancer can achieve the effect in some degree, but it might damage the nasal mucosa. The in situ gel for nasal administration can avoid both the gastrointestinal first pass effect and the drug quickly clearance because it can prolong the retained time of drug in administration site. Based on recent literatures, this review describes the current status of poloxamer 407 in situ gel for nasal drug delivery system, which includes its conception, characteristics, formulation factors effects on drug absorption and applications.

关 键 词：鼻腔给药系统 原位凝胶 吸收 生物利用度 

分 类 号：R943[医药卫生—药剂学]